Pyxis Oncology (NASDAQ:PYXS) Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Pyxis Oncology from “sell” to “hold.” Overall, analysts have a “Moderate Buy” consensus, with seven Buy ratings, one Sell rating, and an average price target of $8.71.
• Analyst price targets varied: Wells Fargo raised its target to $19, while Wedbush lowered its target to $7; RBC also set a $7 target and maintained an Outperform rating.
• Pyxis reported a quarterly loss of $0.24 per share, beating analysts’ estimate of a $0.27 loss. The stock opened at $1.66 and has traded between $1.03 and $5.55 over the past year.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

PYXS has been the topic of a number of other research reports. Wedbush cut their target price on Pyxis Oncology from $8.00 to $7.00 and set an "outperform" rating on the stock in a research note on Friday. Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a report on Thursday. Royal Bank Of Canada upped their price target on shares of Pyxis Oncology from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday. Wells Fargo & Company lifted their target price on Pyxis Oncology from $12.00 to $19.00 and gave the company an "overweight" rating in a report on Wednesday, September 9th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Pyxis Oncology in a research note on Friday, September 25th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.71.

Pyxis Oncology Trading Up 3.1%

PYXS opened at $1.66 on Friday. The business's 50-day simple moving average is $2.51 and its 200-day simple moving average is $2.16. Pyxis Oncology has a one year low of $1.03 and a one year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. On average, sell-side analysts anticipate that Pyxis Oncology will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in Pyxis Oncology by 14.8% during the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company's stock valued at $114,000 after purchasing an additional 6,295 shares in the last quarter. T3 Companies LLC acquired a new position in Pyxis Oncology during the third quarter worth approximately $61,000. Finally, Renaissance Technologies LLC lifted its stake in Pyxis Oncology by 22.0% during the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company's stock worth $1,297,000 after purchasing an additional 160,300 shares during the last quarter. Hedge funds and other institutional investors own 39.07% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology's pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.